Trop-2 antibody-drug conjugate
Showing 1 - 25 of >10,000
Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)
Withdrawn
- Relapsed Solid Neoplasm
- +2 more
- STI-3258
- (no location specified)
Jan 24, 2023
Cervical Cancer Trial (Sacituzumab Govitecan)
Not yet recruiting
- Cervical Cancer
- Sacituzumab Govitecan
- (no location specified)
Apr 18, 2023
Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)
Not yet recruiting
- Advanced Solid Tumors
- LCB84
- Anti-PD-1 monoclonal antibody
-
Los Angeles, California
- +6 more
Jul 4, 2023
Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)
Not yet recruiting
- Ovarian Carcinoma
- Sacituzumab govitecan
-
New Haven, ConnecticutSmilow Cancer Hospital at Yale New Haven
Aug 31, 2023
Endometrial Carcinoma Trial in New Haven (Sacituzumab Govitecan)
Recruiting
- Endometrial Carcinoma
- Sacituzumab Govitecan
-
New Haven, ConnecticutSmilow Cancer Hospital at Yale New Haven
Apr 4, 2022
Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)
Active, not recruiting
- Breast Cancer
- SHR-A1811
- TROP2 ADC
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 11, 2023
Light Chain (AL) Amyloidosis Trial (STI-6129)
Not yet recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
- (no location specified)
Jan 11, 2023
Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Neuroendocrine Carcinomas
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Sep 22, 2023
Advanced Solid Tumors Trial (BAT8008 for Injection)
Not yet recruiting
- Advanced Solid Tumors
- BAT8008 for Injection
- (no location specified)
Nov 9, 2022
Light Chain (AL) Amyloidosis Trial in New York (STI-6129)
Recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
-
Duarte, California
- +3 more
Jan 12, 2023
Reporting of Antibody-Drug Conjugate Associated Sepsis-related
Completed
- Sepsis (SMQ)
- +2 more
- Antibody-Drug Conjugate
- Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
-
Changsha, Hunan, ChinaCentral South University
Jun 19, 2022
Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- STI-6129
-
Beijing, Beijing, China
- +3 more
Jan 9, 2023
Breast Cancer Trial in Boston (Talazoparib, Sacituzumab Govitecan)
Recruiting
- Breast Cancer
- Talazoparib
- Sacituzumab Govitecan
-
Boston, Massachusetts
- +1 more
Jan 6, 2023
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer Trial in Australia (IKS014)
Not yet recruiting
- Breast Cancer
- +2 more
-
Concord, New South Wales, Australia
- +4 more
May 30, 2023
Multiple Myeloma Trial in Canton (STI-6129)
Recruiting
- Multiple Myeloma
- STI-6129
-
Canton, OhioGabrail Cancer Center
Jun 29, 2022
Cancer Trial (Antibody-Drug Conjugate)
Not yet recruiting
- Cancer
- Antibody-Drug Conjugate
- (no location specified)
Aug 23, 2023
Advanced Solid Tumor Trial in New York (STI-6129)
Not yet recruiting
- Advanced Solid Tumor
- STI-6129
-
New York, New YorkColumbia University Medical Center
Jan 26, 2023
Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting
Recruiting
- Breast Neoplasms
- Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
-
Shenyang, Liaoning, ChinaShengjing Hospital affiliated to China Medical University
Jul 30, 2022
Solid Tumor Trial in Belgium, Netherlands, United Kingdom (SYD985 + Niraparib)
Active, not recruiting
- Solid Tumor
- SYD985 + Niraparib
-
Antwerp, Belgium
- +5 more
Jan 23, 2023
